VIRVir Biotechnology, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $69M
- 7.6% YoY
- Operating margin
- -699.2%
- 12% YoY
- EBITDA
- −$468M
- 18% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired72% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.6B | $86M | $74M | $69M | 7.6% |
| Operating income | $421M | $833M | −$684M | −$587M | −$479M | 18% |
| Net income | $529M | $516M | −$615M | −$522M | −$438M | 16% |
| Operating cash flow | −$48M | $1.7B | −$779M | −$446M | −$392M | 12% |
| Capex | $22M | $68M | $22M | $7M | $5M | 34% |
| Stock-based comp | $84M | $102M | $111M | $78M | $49M | 37% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $3M | 23 | 125 |
| FY2024 | — | — | 27 | 93 |
| FY2023 | — | — | 38 | 94 |
| FY2022 | — | — | 95 | 90 |
| FY2021 | — | — | 156 | 100 |